ACCENTMICST Stock Price Today (NSE: ACCENTMIC)
Fundamental Score
ACCENTMICST Share Price — Live NSE/BSE Price, Fundamentals & Analysis
ACCENTMICST share price today is ₹267.00, up +0.00% on NSE/BSE as of 1 August 2026. ACCENTMICST (ACCENTMIC) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.25K (Cr). The 52-week high for ACCENTMIC share price is ₹324.00 and the 52-week low is ₹238.00. At a P/E ratio of 28.52x, ACCENTMIC is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 18.65% and a debt-to-equity ratio of 0.00.
ACCENTMICST Share Price Chart — NSE/BSE Historical Performance
ACCENTMICST share price chart: 9.65% return over the past month. 52-week high ₹324.00, 52-week low ₹238.00.
ACCENTMICST — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹272.00 | ₹273.00 | ₹267.00 | ₹267.00 | 5.50K (Cr) | |
| ₹271.20 | ₹274.00 | ₹267.55 | ₹271.00 | 5.50K (Cr) | |
| ₹275.00 | ₹277.55 | ₹271.00 | ₹271.55 | 8.50K (Cr) | |
| ₹276.50 | ₹278.00 | ₹268.00 | ₹277.55 | 21.00K (Cr) | |
| ₹271.80 | ₹279.00 | ₹268.00 | ₹275.40 | 9.00K (Cr) | |
| ₹275.00 | ₹278.00 | ₹269.50 | ₹274.55 | 18.50K (Cr) | |
| ₹269.00 | ₹284.30 | ₹268.20 | ₹283.55 | 51.00K (Cr) | |
| ₹259.00 | ₹270.80 | ₹253.00 | ₹270.80 | 44.50K (Cr) | |
| ₹264.90 | ₹267.00 | ₹253.75 | ₹257.95 | 10.50K (Cr) | |
| ₹274.00 | ₹280.00 | ₹255.10 | ₹256.90 | 41.00K (Cr) |
ACCENTMICST — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹248.00 | ₹284.30 | ₹238.00 | ₹267.00 | +7.66% | |
| ₹282.10 | ₹292.00 | ₹240.00 | ₹244.95 | -13.17% | |
| ₹312.50 | ₹320.00 | ₹278.25 | ₹284.15 | -9.07% |
AI Research Briefing
Powered by Gemini · 2026-08-01
Impressive 50%+ profit growth is severely undercut by negative ₹68 Cr 5Y free cash flow, insider dumping, and CRISIL non-cooperation flags.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Company scheduled its 14th Annual General Meeting for July 31, 2026, following a ₹1.00 dividend payout announcement. High-profile insider activity dominated July, where promoter/insider Ghanshyam Arjanbhai Patel executed a major bulk deal sell-off of 390,000 shares on July 20, 2026, following his earlier liquidation of 586,000 shares in June. Meanwhile, full-year FY26 results showed revenues jumping 34% YoY to ₹356 crore and net profit reaching ₹43.86 crore (EPS ₹18.65 vs ₹15.71). However, CRISIL flagged credit concerns by classifying its ₹20.92 crore bank facilities under Issuer Not Cooperating due to lack of management engagement.
CORE STORY (THE REAL GAME)
This is an excipient and specialized microcrystalline cellulose (MCC) manufacturing play riding the Indian pharmaceutical export boom. Markets are attempting to price it as a high-margin specialty chemical/excipient compounder, but the reality is an SME-origin player facing severe working capital absorption and poor cash flow conversion despite pristine top-line growth.
- FY26 full-year revenue reported up 34% YoY to ₹356 crore with net profit up 33% to ₹43.86 crore.
- Promoter/insider Ghanshyam Patel offloaded 390,000 shares in bulk deal on July 20, 2026.
- Annual General Meeting hosted on July 31, 2026, following a ₹1.00 dividend announcement.
- Q1/Q2 earnings prints demonstrating positive working capital cycle shift.
- CRISIL credit rating upgrade or clearance from 'Issuer Not Cooperating' status.
- Stabilization or reversal of promoter/insider selling in open market.
- Severe negative free cash flow: 5Y FCF stands at ₹-68.14 crore despite high net profits.
- CRISIL downgraded ₹20.92 Cr bank facility rating to 'Issuer Not Cooperating' due to management non-engagement.
- Repeated large bulk deal sell-offs by major shareholders.
Promoter holding flat at 55.47% (Δ +0.03%), FII holding remains negligible at 0.58% (Δ +0.29%), and DII at 3.59% (Δ +0.02%), showing low institutional depth.
Government of India's ₹60,000 Cr API/pharma manufacturing push provides structural demand, offset by global export tariff friction.
No major individual order contract wins disclosed in live search; FY26 total revenue reached ₹356 crore.
Extremely poor cash conversion; net profit of ₹43.86 Cr in FY26 accompanied by negative free cash flow due to heavy working capital lockup.
P&L growth will stay strong due to demand for excipients, but stock faces valuation caps unless cash flow generation turns positive. Monitor working capital and insider deal disclosures closely.
Primary Thesis Risk
High accounting profit with negative free cash flow risks sudden earnings quality write-downs.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
ACCENTMICST Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
ACCENTMICST Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ACCENTMIC across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Strong Return on Equity (18.65%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (24.88%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Robust Profit Growth (55.36%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (51.34%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (21.36% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (54.27% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (108.89x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (55.47%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Negative Free Cash Flow (₹-68.14 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 4.17%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
ACCENTMICST vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare ACCENTMICST with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
ACCENTMICSTACCENTMICST...Selected✓ ACCENTMIC • | 75.2/100 | ₹267.00₹267 | ₹1251.02₹1251.02 | 28.52Average 28.5 Average | 18.65%Good 18.65% Good | 24.88%Excellent 24.88% Excellent | 0.00Excellent 0.0 Excellent | 54.27%Excellent 54.27% Excellent | 21.36%Excellent 21.36% Excellent | 0.19% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
ACCENTMICST PE Ratio History
Historical price-to-earnings ratio for ACCENTMIC — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2023 | ₹5.81 | ₹292.40 | 50.3x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
ACCENTMICST Dividend History
Annual cash dividends paid by ACCENTMIC — dividend yield 0.19%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2024 | ₹1.04 Cr |
| FY 2023 | ₹1.03 Cr |
| FY 2022 | ₹0.43 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
ACCENTMICST Quarterly Performance
Latest quarterly metrics for ACCENTMIC — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
51.34%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
55.36%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
21.36%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
54.27%
Compounded annual net profit growth over 5 years
ACCENTMICST Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ACCENTMIC — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
ACCENTMICST Financial Statements
Annual income statement, balance sheet and cash flow for ACCENTMICST (ACCENTMIC) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for ACCENTMICST
About ACCENTMIC (ACCENTMICST)
ACCENTMICST (ACCENTMIC) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current m...arket capitalisation of ₹1.25K (Cr). ACCENTMICST has delivered a Return on Equity (ROE) of 18.65% and a ROCE of 24.88%. The debt-to-equity ratio stands at 0.00, reflecting the company's capital structure. Investors tracking ACCENTMIC share price can monitor key metrics including P/E ratio, promoter holding of 55.47%, and quarterly earnings growth.
Company Details
ACCENTMIC Share Price: Frequently Asked Questions
What is the current share price of ACCENTMICST?
ACCENTMICST (ACCENTMIC) trades at ₹267.00 on NSE. Market cap ₹1.25K (Cr). Educational data only.
What is the P/E ratio of ACCENTMICST?
ACCENTMICST has a P/E of 28.52x vs industry average 34.89x.
What is the Bull Run score for ACCENTMICST?
ACCENTMICST has a Bull Run score of 75.2/100 based on 25+ financial parameters.
Does ACCENTMICST pay dividends?
ACCENTMICST has a dividend yield of 0.19%. Past dividends don't guarantee future payments.
What is the ROE of ACCENTMICST?
ACCENTMICST has ROE of 18.65%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of ACCENTMICST?
ACCENTMICST has debt-to-equity of 0.00.
Is ACCENTMICST a good investment?
Bull Run gives ACCENTMICST a score of 75.2/100. This is not investment advice — consult a SEBI-registered advisor.